Pfizer's tofacitinib for RA accepted for review in Europe
This article was originally published in Scrip
Executive Summary
Pfizer has said that the marketing authorisation application for its oral JAK inhibitor, tofacitinib (CP-690,550), for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been accepted for review by the European Medicines Agency (EMA).